Miettunen, Paivi M. H.; Xingchang Wei; Kaura, Deepak; Reslan, Walid Abou; Aguirre, Alberto Nettel; Kellner, James D.
November 2009
Romanian Journal of Pediatrics;2009, Vol. 58 Issue 4, p360
Academic Journal
Background: Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory, noninfectious osteopathy that affects predominantly patients ≤ 18 years of age. There is no uniformly effective treatment. Our objective is to describe clinical, magnetic resonance imaging (MRI), and bone resorption response to intravenous pamidronate in pediatric CRMO. Methods: We report our prospectively documented experience with all CRMO patients treated with pamidronate between 2003 and 2008 at a tertiary pediatric centre. Pamidronate was administered as intravenous cycles. The dose of pamidronate varied among subjects but was given as monthly to every 3 monthly cycles depending on the distance the patient lived from the infusion center. Maximum cumulative dose was ≤ 11.5 mg/kg/year. Pamidronate treatment was continued until resolution of MRI documented bone inflammation. Visual analog scale for pain (VAS) and bone resorption marker urine N-telopeptide/urine creatinine (uNTX/uCr) were measured at baseline, preceding each subsequent pamidronate treatment, at final follow-up, and/or at time of MRI confirmed CRMO flare. MRI of the affected site(s) was obtained at baseline, preceding every 2nd treatment, and with suspected CRMO recurrence. Results: Nine patients (5 F: 4 M) were treated, with a median (range) age at treatment of 12.9 (4.5-16.3) years, and median (range) duration of symptoms of 18 (6-36) months. VAS decreased from 10/10 to 0-3/10 by the end of first 3-day treatment for all patients. The mean (range) time to complete MRI resolution of bone inflammation was 6.0 (2-12) months. The mean (confidence interval (CI)) baseline uNTX/uCr was 738.83 (CI 464.25, 1013.42)nmol/mmol/creatinine and the mean (CI) decrease from baseline to pamidronate discontinuation was 522.17 (CI 299.77, 744.56)nmol/mmol/creatinine. Median (range) of follow-up was 31.4 (24-54) months. Four patients had MRI confirmed CRMO recurrence, which responded to one pamidronate re-treatment. The mean (range) uNTX/uCr change as a monthly rate from the time of pamidronate discontinuation to flare was 9.41 (1.38-19.85)nmol/mmol/creatinine compared to -29.88 (-96.83-2.01)nmol/mmol/creatinine for patients who did not flare by the time of final follow-up. Conclusion: Pamidronate resulted in resolution of pain and MRI documented inflammation in all patients. No patient flared while his/her uNTX/uCr remained suppressed. We propose that pamidronate is an effective second-line therapy in persistent CRMO.


Related Articles

  • Bony sequestrum: a radiologic review. Jennin, Félicie; Bousson, Valérie; Parlier, Caroline; Jomaah, Nabil; Khanine, Vanessa; Laredo, Jean-Denis; Jennin, Félicie; Bousson, Valérie // Skeletal Radiology;Aug2011, Vol. 40 Issue 8, p963 

    According to a pathological definition, a bony sequestrum is defined as a piece of devitalized bone that has been separated from the surrounding bone during the process of necrosis. However, the radiological definition of a sequestrum is different and refers to an image of calcification visible...

  • Diagnostic imaging of pediatric hematogenous osteomyelitis: lessons learned from a multi-modality approach. Santos, José M. Mellado // European Radiology;Sep2006, Vol. 16 Issue 9, p2109 

    Pediatric hematogenous osteomyelitis may present highly variable radiological expression, which is influenced by the age and condition of the patient, the virulence of the causative agent, the stage of the disease, or the selected imaging tool. Given the multiplicity of available modalities and...

  • Osteomyelitis and beyond. Guillerman, R. // Pediatric Radiology;Mar2013 Supplement, Vol. 43, p193 

    Musculoskeletal infections are a cause of considerable morbidity in children. Symptoms and signs are often nonspecific, and imaging is needed to define the anatomical location of infected tissue or fluid collections for diagnostic aspiration or biopsy. Prompt diagnosis and precise localization...

  • Pediatric Pelvic Osteomyelitis. Klein, Joel D.; Leach, Kathleen A. // Clinical Pediatrics;Nov2007, Vol. 46 Issue 9, p787 

    Pelvic osteomyelitis is unusual in children. We retrospectively reviewed charts of patients with this infection seen at our institution. From 1998 to 2005, 31 patients with pelvic osteomyelitis were identified: 19 males and 12 females with an age range of 1.5 months to 17 years 9 months....

  • Significance of epiphyseal cartilage enhancement defects in pediatric osteomyelitis identified by MRI with surgical correlation. Johnson, David; Hernanz-Schulman, Marta; Martus, Jeffrey; Lovejoy, Steven; Chang Yu; Kan, J. // Pediatric Radiology;Mar2011, Vol. 41 Issue 3, p355 

    Background: Epiphyseal cartilage enhancement defects (ED) may occur in the setting of epiphyseal osteomyelitis (OM), and its significance is uncertain. Objective: The aim of this study is to evaluate the incidence and clinical impact of epiphyseal cartilage ED in pediatric epiphyseal OM....

  • MRI of subchondral fractures: a review. Viana, Sergio; Machado, Bruno; Mendlovitz, Paulo // Skeletal Radiology;Nov2014, Vol. 43 Issue 11, p1515 

    Several authors have recently emphasized the role of magnetic resonance imaging (MRI) in the diagnosis of subchondral fractures. There is increasing interest about this type of fractures, mostly because they have been implicated in the genesis of some well-known destructive articular conditions...

  • Monitoring and Risk of Progression of Osteolysis After Total Hip Arthroplasty. Ries, Michael D.; Link, Thomas M. // Journal of Bone & Joint Surgery, American Volume;11/21/2012, Vol. 94-A Issue 22, p2097 

    The article presents a study on the risk of progression and monitoring of osteolysis after total hip arthroplasty. It notes that the development of osteolysis after total hip arthroplasty is influenced by wear volume, which heightens with use and patient activity. It recommends that patients...

  • Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Samani, Khalil; Brazier, Michel; Mathiot, Claire; Kamel, Saïd; Jamart, Jacques; Jaubert, Jerome; Blanc, Michel; Azaïs, Isabelle; Facon, Thierry; Leleu, Xavier // Annals of Hematology;Jan2005, Vol. 84 Issue 1, p19 

    Bone disease is a common feature of multiple myeloma (MM). The goal of this study was to assess the prognostic significance of urinary markers of bone metabolism in MM. Urinary levels of total pyridinoline (T-Pyd), deoxypyridinoline (T-Dpd), crosslinkedN-telopeptide (Ntx),C-telopeptide (Ctx) of...

  • Intra-individual, randomised comparison of the MRI contrast agents gadobutrol and gadoterate in imaging the distal lower limb of patients with known or suspected osteomyelitis, evaluated in an off-site blinded read. Pennekamp, Werner; Roggenland, Daniela; Hering, Steffen; Lemburg, Stefan; Peters, Soeren; Sterl, Sabrina; Schwenke, Carsten; Nicolas, Volkmar // European Radiology;May2011, Vol. 21 Issue 5, p1058 

    Objective: To prove that 1.0 M gadobutrol provides superior contrast enhancement in suspicion of osteomyelitis of the feet compared with 0.5 M gadoterate. Methods: MRI of feet was performed on 2 separate occasions. Independent injections of 1.0 M gadobutrol and 0.5 M gadoterate at doses of 0.1...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics